Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Theilacker

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The Journal of Infection|February 14, 2025
Incidence of RSV-related hospitalizations for ARIs, including CAP: Data from the German prospective ThEpiCAP studyCaihua Liang, Elizabeth Begier, Stefan Hagel, et al.
Vaccine|February 9, 2024
Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UKCatherine Hyams, Maria Lahuerta, Christian Theilacker, et al.
Microorganisms|January 21, 2023
Prevalence of Pneumococcal Serotypes in Community-Acquired Pneumonia among Older Adults in Italy: A Multicenter Cohort StudyAndrea Orsi, Alexander Domnich, Stefano Mosca, et al.
The Lancet. Infectious Diseases|May 3, 2026
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort studyAmanda C Miles, Jelena Vojicic, Paula Peyrani, et al.
BMJ Open|July 7, 2022
Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2)Konstantinos Liatsikos, Angela Hyder-Wright, Sherin Pojar, et al.
The Lancet. Microbe|February 16, 2026
The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trialKonstantinos Liatsikos, Angela Hyder-Wright, Kelly Davies, et al.
Plos One|July 1, 2025
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocolSanjita Brito-Mutunayagam, David O Hamilton, Elena Mitsi, et al.
American Journal of Respiratory and Critical Care Medicine|July 8, 2022
Human Infection Challenge with Serotype 3 PneumococcusRyan E Robinson, Elena Mitsi, Elissavet Nikolaou, et al.
The Journal of Clinical Investigation|February 9, 2022
Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2Elena Mitsi, Jesús Reiné, Britta C Urban, et al.
The Journal of Infectious Diseases|July 16, 2024
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in CommunitiesDima El Safadi, Lisa Hitchins, Ashleigh Howard, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The Journal of Infection|February 14, 2025
Incidence of RSV-related hospitalizations for ARIs, including CAP: Data from the German prospective ThEpiCAP studyCaihua Liang, Elizabeth Begier, Stefan Hagel, et al.
Vaccine|February 9, 2024
Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UKCatherine Hyams, Maria Lahuerta, Christian Theilacker, et al.
Microorganisms|January 21, 2023
Prevalence of Pneumococcal Serotypes in Community-Acquired Pneumonia among Older Adults in Italy: A Multicenter Cohort StudyAndrea Orsi, Alexander Domnich, Stefano Mosca, et al.
The Lancet. Infectious Diseases|May 3, 2026
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort studyAmanda C Miles, Jelena Vojicic, Paula Peyrani, et al.
BMJ Open|July 7, 2022
Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2)Konstantinos Liatsikos, Angela Hyder-Wright, Sherin Pojar, et al.
The Lancet. Microbe|February 16, 2026
The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trialKonstantinos Liatsikos, Angela Hyder-Wright, Kelly Davies, et al.
Plos One|July 1, 2025
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocolSanjita Brito-Mutunayagam, David O Hamilton, Elena Mitsi, et al.
American Journal of Respiratory and Critical Care Medicine|July 8, 2022
Human Infection Challenge with Serotype 3 PneumococcusRyan E Robinson, Elena Mitsi, Elissavet Nikolaou, et al.
The Journal of Clinical Investigation|February 9, 2022
Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2Elena Mitsi, Jesús Reiné, Britta C Urban, et al.
The Journal of Infectious Diseases|July 16, 2024
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in CommunitiesDima El Safadi, Lisa Hitchins, Ashleigh Howard, et al.
Pageof 7